Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a 
topical formulation of a fixed and stable combination approved by the FDA for 
the treatment of acne vulgaris in patients 12 years of age or older. The main 
indication of CTG is the management of moderate comedonal and mild-to-moderate 
papulopustular acne, an acne form which is present in more than 50% of acne 
patients. CTG can also be combined with systemic antiacne therapy, such as 
systemic isotretinoin, in nodulocystic acne. The product combines the 
anti-inflammatory and antibacterial properties of clindamycin with the well 
proven and beneficial comedolytic and anticomedogenic effects of tretinoin 
(all-trans retinoic acid). The addition of clindamycin to tretinoin enhances the 
comedolytic efficacy of tretinoin in moderate-to-severe acne of the face. The 
comedolytic activity of tretinoin and the anti-inflammatory efficacy of 
clindamycin accelerate resolution of all types of acne lesions without affecting 
the safety of both compounds. Discontinuation rates due to adverse events 
related to this formulation were found to be low (</= 1%). Safety of CTG use in 
pregnancy has not been established. The combination formulation is mainly 
designed to enhance effectiveness and minimize irritation. The once daily use of 
CTG, its rapid and dual effect and good tolerability have a positive impact on 
the duration of disease, patients' compliance and overall costs of therapy.